Management of indolent B-cell Lymphomas: A review of approved and emerging targeted therapies
Cancer Treatment Reviews · 2023
DOI: 10.1016/j.ctrv.2023.102510 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2023. Verfasst von Elizabeth Smyth und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia. Hauptthemen laut MEDLINE: Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Antineoplastic Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 128 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
- Department of Hematology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia; Medical School, University of Western Australia, Perth, Western Australia, Australia. Electronic address: Chan.cheah@health.w…
- Peter MacCallum Cancer Centre & The Royal Melbourne Hospital, Melbourne, Victoria, Australia; University of Melbourne, Victoria, Australia. Electronic address: John.seymour@petermac.org.
Zitieren
APA
Smyth, E., Cheah, C. Y., & Seymour, J. F. (2023). Management of indolent B-cell Lymphomas: A review of approved and emerging targeted therapies. Cancer Treatment Reviews. https://doi.org/10.1016/j.ctrv.2023.102510
Vancouver
Smyth E, Cheah CY, Seymour JF. Management of indolent B-cell Lymphomas: A review of approved and emerging targeted therapies. Cancer Treatment Reviews. 2023. doi:10.1016/j.ctrv.2023.102510
BibTeX
@article{Smyth2023,
author = {Smyth, Elizabeth and Cheah, Chan Y and Seymour, John F},
title = {Management of indolent B-cell Lymphomas: A review of approved and emerging targeted therapies},
journal = {Cancer Treatment Reviews},
year = {2023},
doi = {10.1016/j.ctrv.2023.102510}
}
EUVIMED